Crossmark

Management of immune thrombocytopenia in multiple sclerosis patients treated with alemtuzumab: a Belgian consensus

Crossref DOI link: https://doi.org/10.1007/s13760-018-0882-3

Published Online: 2018-01-27

Published Print: 2018-03

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Lambert, Catherine http://orcid.org/0000-0003-2222-0357
Dubois, Benedicte

Dive, Dominique

Lysandropoulos, Andreas

Selleslag, Dominik

Vanopdenbosch, Ludo

Van Pesch, Vincent

Vanwijmeersch, Bart

Janssens, Ann
License Information

Text and Data Mining valid from 2018-01-27
More Information

Article History

Received: 1 December 2017

Accepted: 9 January 2018

First Online: 27 January 2018

Change Date: 3 March 2018

Change Type: Correction

Change Details: The article Management of immune thrombocytopenia in multiple sclerosis patients treated with alemtuzumab: a Belgian consensus, written by Lambert et al., was originally published electronically on the publisher’s internet portal on 27 January 2018 without open access.

Compliance with ethical standards

:

: The authors declare they have no conflict of interest.

: This article does not contain any studies with human participants performed by any of the authors.

: For this type of article informed consent is not necessary.